gemcitabine has been researched along with 3-hydroxyflavone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MJ; Kim, BH; Kim, N; Kim, YT; Lee, JM; Lee, JS; Lee, SH; Ryu, JK; Son, JH | 1 |
| Kang, MJ; Kim, N; Kim, YT; Lee, JE; Lee, SH; Paik, WH; Ryu, JK; Son, JH | 1 |
2 other study(ies) available for gemcitabine and 3-hydroxyflavone
| Article | Year |
|---|---|
Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells.
Topics: Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Flavonoids; Flavonols; Gemcitabine; Humans; MAP Kinase Signaling System; Phosphorylation; Up-Regulation | 2016 |
Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Flavonols; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc | 2018 |